An interventional study of Proactive E-consult in COPD and HIV/AIDS, sponsored by Seattle Institute for Biomedical and Clinical Research. Completed at 7 sites in United States. Open to participants aged 18 Years to 89 Years. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by Seattle Institute for Biomedical and Clinical Research · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,280 studies in Pulmonary Disease, Chronic Obstructive with a site in United States — 139 open to participants now, 174 under way, 21 of them phase 3. Pulmonary Disease, Chronic Obstructive · United States.
Among the 1,280 studies in Pulmonary Disease, Chronic Obstructive with a site in United States, this one is the 294th largest by enrollment of the 1,039 interventional ones that give a count, is one of 58 that started in 2019, is one of 395 with no phase, and was the 908th registered.
5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →139 of the 1,280 studies in Pulmonary Disease, Chronic Obstructive with a site in United States are open now. Recruiting first, the newest first:
University of California, Berkeley · Sites in United States
Ages 13+
Cedars-Sinai Medical Center · Sites in United States
Ages 18+
Merck Sharp & Dohme LLC · Sites in United States
Ages 40–80
GlaxoSmithKline · Sites in United States, United Kingdom
Ages 40–80
Johns Hopkins University · Sites in United States
Ages 18–75 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.
This study: 18 Years to 89 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,280 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 117 · Phase 2 231 · Phase 3 239 · Phase 4 98
First in 1994; this study’s year is marked. 58 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 346 is above the median of 62 across 3,847 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 100 across the 1,039 interventional studies, 171 across the 237 observational. Of the 1,018 that completed or were terminated, 503 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
605 of 1,280 have an industry lead sponsor. The 10 most frequent:
Seattle Institute for Biomedical and Clinical Research is the lead sponsor of 49 studies on the registry; 4 are open to participants now.
Seattle Institute for Biomedical and Clinical Research has 4 studies filed under Pulmonary Disease, Chronic Obstructive — fewer than ten, so there is no comparison to draw.
62 of the studies in Pulmonary Disease, Chronic Obstructive with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05265299Phase 3Johns Hopkins UniversityTrial to Determine Effective Aspirin Dose in COPD | 2026-12 |
| NCT05878769Phase 3Hoffmann-La RocheA Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD) | 2027-06-30 |
| NCT07555483Phase 3Grifols Therapeutics LLCA Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD) | 2027-09-30 |
| NCT04968249University of MichiganMichigan Early Disease Progression Cohort | 2026-12 |
| NCT05879211Duke UniversityGoal Concordant Care Learning Laboratory | 2026-12 |
Add all 62 to your calendar (.ics) → With an account.
Among the 1,280 studies in Pulmonary Disease, Chronic Obstructive with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study examines an intervention to promote effective, evidence-based care and de-implement inappropriate therapies for COPD in HIV-infected (HIV+) patients. The intervention facilitates specialist support of primary care, which includes infectious disease (ID) physicians who serve as the primary care providers (PCP) for their HIV+ patients in the ID clinic. Rather than relying on referral-driven specialty care which may be a barrier to access, pulmonologists will proactively support ID providers to manage a population of HIV+ patients with COPD, delivering real-time evidence-based recommendations tailored to the individual HIV+ patient in the form of an E-consult.
Emerging data support that barriers to high quality COPD care are likely accentuated in HIV+ persons. Taken together, decreased recognition of smoking, lack of referral for pulmonary evaluation, worse symptoms and greater exacerbation rates point towards low quality of care for COPD in HIV+ patients. Our preliminary data supports that COPD is inadequately managed in HIV+ patients. These data demonstrate that current management of COPD in HIV+ patients do not adhere to guidelines, that ICS may be over-prescribed and long-acting bronchodilators under-utilized, and support the need to improve evidence-based COPD care in HIV+ patients. Appropriate use of COPD therapies is particularly important for HIV+ patients, as side effects and toxicities could be more harmful in HIV+ patients, given their concomitant multimorbidity and polypharmacy. In summary, an intervention to improve the evidence-based delivery of COPD care can improve outcomes for HIV+ patients. Benefits may extend beyond COPD-related measures. Appropriate use of COPD controller medications can decrease symptoms and exacerbations, and improve health-related quality of life. Our proposed study to has a high potential to substantially improve the quality of care for COPD and patient-centered outcomes for a large number of HIV+ Veterans.
This study tests an intervention to promote effective, evidence-based care and de-implement inappropriate therapies for COPD in HIV+ patients. The intervention facilitates specialist support of primary care, which includes infectious disease (ID) physicians who serve as the primary care providers (PCP) for their HIV+ patients in the ID clinic. Rather than relying on referral-driven specialty care, which may be a barrier to access, pulmonologists will proactively support ID providers to manage a population of HIV+ patients with COPD, delivering real-time evidence-based recommendations tailored to the individual HIV+ patient. The investigators will leverage the Department of Veterans Affairs (VA) clinical and informatics infrastructures to communicate between intervention-team members developing the recommendations (using VA Extension for Community Health Outcomes [ECHO]) and to patients' clinical providers through the electronic health record (EHR) as an E-consult. To limit the burden on the provider, the intervention team will draft recommendations as preliminary orders for providers to review. To preserve their autonomy, the provider has the discretion to endorse (sign), modify or cancel the orders.
This study uses a two-arm cluster randomized controlled trial intervention design grounded in the chronic care model with outcomes evaluated using the RE-AIM (Reach, Effectiveness, Adoption, Implementation and Maintenance) framework. The investigators will evaluate barriers and facilitators of optimal COPD care for HIV+ patients, and of effective adoption, implementation and maintenance of the proactive E-consult program, guided by the Consolidated Framework for Implementation Research (CFIR).
This study involves the recruitment and enrollment of two populations: providers and patients. Providers will be recruited at the beginning of the study; providers that enroll will be randomly chosen to either provide usual care (control) or to receive E-consults for their HIV+ patients with COPD (intervention). Patients of enrolled providers will be recruited after attending an appointment with their provider. Enrolled patients will be asked to complete a set of surveys, and some patients will be offered the opportunity to participate in an interview about their care.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Providers:
Patients:
Exclusion Criteria:
Providers:
Patients:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Providers in this arm will provide usual care to their HIV+ patients with COPD.
Providers in this arm will receive proactive E-consults with expert recommendations for COPD care prior to appointments with HIV+ patients with COPD.
Behavioral: Proactive E-consult
E-consult recommendations and orders will be developed by a panel of pulmonologists and will address a range of care elements for patients with COPD.
% of COPD Care Recommendations Received by Patients of Enrolled Providers
% of COPD care recommendations received by the patient, examined collectively for each patient and individually by type of recommendation (e.g. use of spirometry, long acting bronchodilator, smoking cessation, vaccination, etc.) to assess the overall quality of COPD care. We will report percentage of actionable care recommendations received by the patient out of the total recommendations sent across all patients, using "Number" as the measure type.
Time frame: Within 6 months following provider/patient appointment
Patient Health-related Quality of Life
Patient-reported health-related quality of life on the Medical Outcomes 12-item short form (SF-12), a patient self-report survey. This survey is a 12-item scale with two subscales (mental and physical components). Summary scores range from 0-100, with higher scores reflecting better health.
Time frame: 6 weeks following provider/patient appointment
HIV Provider Satisfaction With Specialty-care Support
Baseline and follow-up self-report surveys (all participating providers) and interviews (sample of providers)
Time frame: Baseline: prior to intervention roll-out. Follow-up: after exposure to intervention (defined as having received at least 2 E-consults), up to 3 years.
| Milestone | Usual Care (Patients) | Proactive E-consult (Patients) | Usual Care (Providers) | Proactive E-consult (Providers) |
|---|---|---|---|---|
| Started | 140 | 130 | 35 | 41 |
| Completed | 140 | 130 | 35 | 41 |
| Not completed | 0 | 0 | 0 | 0 |
% of COPD care recommendations received by the patient, examined collectively for each patient and individually by type of recommendation (e.g. use of spirometry, long acting bronchodilator, smoking cessation, vaccination, etc.) to assess the overall quality of COPD care. We will report percentage of actionable care recommendations received by the patient out of the total recommendations sent across all patients, using "Number" as the measure type.
| Percentage of recommendations received | Usual Care (Patients) | Proactive E-consult (Patients) |
|---|---|---|
| % of COPD Care Recommendations Received by Patients of Enrolled Providers | 23 | 45 |
Patient-reported health-related quality of life on the Medical Outcomes 12-item short form (SF-12), a patient self-report survey. This survey is a 12-item scale with two subscales (mental and physical components). Summary scores range from 0-100, with higher scores reflecting better health.
Results for this outcome have not been posted.
Baseline and follow-up self-report surveys (all participating providers) and interviews (sample of providers)
Results for this outcome have not been posted.
Collected over Within 1 year following index date. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Usual Care (Patients) | 9/140 (6.4%) | 38/140 (27.1%) | 33/140 (23.6%) |
| Proactive E-consult (Patients) | 8/130 (6.2%) | 26/130 (20%) | 25/130 (19.2%) |
| Event | Usual Care (Patients) | Proactive E-consult (Patients) |
|---|---|---|
| Multiple System InvolvementGeneral disorders | 14/140 | 11/130 |
| COPD ExacerbationRespiratory, thoracic and mediastinal disorders | 4/140 | 5/130 |
| Suicidal IdeationPsychiatric disorders | 5/140 | 2/130 |
| PneumoniaRespiratory, thoracic and mediastinal disorders | 3/140 | 1/130 |
| SepsisRespiratory, thoracic and mediastinal disorders | 0/140 | 2/130 |
| Shortness of BreathRespiratory, thoracic and mediastinal disorders | 0/140 | 2/130 |
| Chest PainCardiac disorders | 2/140 | 1/130 |
| Bone FractureMusculoskeletal and connective tissue disorders | 2/140 | 0/130 |
| Respiratory Distress/FailureRespiratory, thoracic and mediastinal disorders | 2/140 | 1/130 |
| UTIRenal and urinary disorders | 2/140 | 0/130 |
| Event | Usual Care (Patients) | Proactive E-consult (Patients) |
|---|---|---|
| Multiple System InvolvementGeneral disorders | 8/140 | 4/130 |
| COVID-19 Infection/SymptomsRespiratory, thoracic and mediastinal disorders | 2/140 | 6/130 |
| Skin Rash/DiscomfortSkin and subcutaneous tissue disorders | 1/140 | 5/130 |
| Back/Neck PainMusculoskeletal and connective tissue disorders | 4/140 | 0/130 |
| Leg/Knee PainMusculoskeletal and connective tissue disorders | 4/140 | 2/130 |
| Ankle/foot PainMusculoskeletal and connective tissue disorders | 2/140 | 3/130 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/140 | 3/130 |
| Shortness of BreathRespiratory, thoracic and mediastinal disorders | 3/140 | 2/130 |
| BronchitisRespiratory, thoracic and mediastinal disorders | 3/140 | 1/130 |
| Ostomy Bag Leak/Suture RemovalGastrointestinal disorders | 0/140 | 2/130 |
Our baseline analysis describes patients that were enrolled in the usual care or proactive E-consult arms and providers who had proactive E-consults for their patients.
| Age, Categorical(Participants) | Usual Care (Patients) | Proactive E-consult (Patients) | Usual Care (Providers) | Proactive E-consult (Providers) | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 68 | 64 | 18 | 18 | 168 |
| >=65 years | 72 | 66 | 1 | 6 | 145 |
| Age, Continuous(Years) | Usual Care (Patients) | Proactive E-consult (Patients) | Usual Care (Providers) | Proactive E-consult (Providers) | Total |
|---|---|---|---|---|---|
| Median | 65 (60 to 70) | 65 (60 to 70) | 49 (35 to 61) | 46 (36 to 64) | 64 (59 to 70) |
| Sex: Female, Male(Participants) | Usual Care (Patients) | Proactive E-consult (Patients) | Usual Care (Providers) | Proactive E-consult (Providers) | Total |
|---|---|---|---|---|---|
| Female | 4 | 7 | 9 | 8 | 28 |
| Male | 136 | 123 | 10 | 10 | 279 |
| Race (NIH/OMB)(Participants) | Usual Care (Patients) | Proactive E-consult (Patients) | Usual Care (Providers) | Proactive E-consult (Providers) | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 0 | 0 | 1 |
| Asian | 1 | 0 | 3 | 1 | 5 |
| Native Hawaiian or Other Pacific Islander | 2 | 0 | 0 | 0 | 2 |
| Black or African American | 89 | 76 | 0 | 0 | 165 |
| White | 45 | 52 | 6 | 8 | 111 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 2 | 2 | 13 | 18 | 35 |
| Region of Enrollment(Participants) | Usual Care (Patients) | Proactive E-consult (Patients) | Usual Care (Providers) | Proactive E-consult (Providers) | Total |
|---|---|---|---|---|---|
| United States | 140 | 130 | 22 | 27 | 319 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from May 2019 to primary completion in May 2025, 72 months.
Results were first posted in Nov 2026, 1 year 5 months after primary completion.
Of 1,099 non-industry interventional studies with no phase under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's 72 months is above that.
Counting every sponsor, half of 1,187 studies reached it within 22 months; a quarter within 10 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Disease, Chronic Obstructive →
Seattle Institute for Biomedical and Clinical Research